InSite Vision is focused on the advancement of new and superior ophthalmologic products for unmet eye care needs. InSite’s product portfolio utilizes InSite Vision’s proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections: AzaSite® 1%, marketed in the U.S. by Merck; and Besivance® 0.6%, marketed by Bausch + Lomb. For more information visit the company’s Web site at www.insitevision.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below: